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INTRODUCTION
Myeloablative conditioning regimens with high-dose
chemotherapy, with or without a lethal dose of total body
irradiation, have been applied to eradicate underlying
disease and suppress the host’s immune system to achieve
engraftment and disease control in allogeneic
hematopoietic stem cell transplantation (HSCT). This type
of HSCT causes profound marrow suppression and organ
toxicity. Recently, nonmyeloablative stem cell
transplantation (NST) has been widely and increasingly
used in clinical allogeneic HSCT, based on findings that
engraftment can also be succeeded by nonmyeloablative
conditioning regimens, which are mainly composed of
immune suppression. The term reduced-intensity
allogeneic hematopoietic stem cell transplnantation
(RIST) is also used for any transplantation that uses a
conditioning regimen other than myeloablative. Although
a RIST regimen that is of minimal intensity is called NST
in a strict sense, the term NST is synonymously used with
RIST in the present review. Originally, NST was developed
by several researchers about 10 years ago [1-7]. NST is
beneficial for older patients (generally over 50-55 years
old) and those with comorbidities because
nonmyeloablative conditioning regimens are less toxic for
the bone marrow as well as the other organs and tissues,
resulting in reduced transplant-related mortality (TRM).
Other major complication such as graft-versus-host
disease (GVHD) usually occur when a conversion occurs
from mixed chimerism to complete donor chimerism,
which is accompanied by the graft-versus-leukemia
(GVL) effect. To obtain complete donor chimerism,
donorlymphocyte infusion (DLI) is the usual procedure
that supports enhanced engraftment and suppresses the
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REVIEW
Nonmyeloablative stem cell transplantation (NST) is increasingly used with beneficial effects because it can be
applied to older patients with hematological malignancies and those with various complications who are not
suitable for conventional myeloablative stem cell transplantation (CST). Various conditioning regimens differ in
their myeloablative and immunosuppressive intensity. Regardless of the type of conditioning regimen, graft-
versus-host disease (GVHD) in NST occurs almost equally in CST, although a slightly delayed development of
acute GVHD is observed in NST. Although graft-versus-hematological malignancy effects (i.e., graft-versus-
leukemia effect, graft-versus-lymphoma effect, and graft-versus-myeloma effect) also occur in NST, completely
eradicating residual malignant cells through allogeneic immune responses is insufficient in cases with rapidly
growing disease or uncontrolled progressive disease. Donor lymphocyte infusion (DLI) is sometimes combined to
support engraftment and to augment the graft-versus-hematological malignancy effect, such as the graft-versus-
leukemia effect. DLI is especially effective for controlling relapse in the chronic phase of chronic myelogenous
leukemia, but not so effective against other diseases. Indeed, NST is a beneficial procedure for expanding the
opportunity of allogeneic hematopoietic stem cell transplantation to many patients with hematological
malignancies. However, a more sophisticated improvement in separating graft-versus-hematological malignancy
effects from GVHD is required in the future. (Korean J Intern Med 2009;24:287-298)
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REVIEWhost-versus-graft reaction, and sometimes induces the
GVL effect [8-14]. However, similar to allogeneic
myeloablative stem cell transplantation, separation of the
GVL effect from GVHD is difficult. 
Allogeneic immune responses can be induced against
other hematological malignancies. An anti-lymphoma or
anti-myeloma effect is also observed after allogenic HSCT
and is called the graft-versus-lymphoma effect or graft-
versus-myeloma effect, respectively. The term GVL effect
is used here to include representatives of graft-versus-
hematological malignancy effects. 
Although NST has been applied to solid tumors such as
renal cell carcinoma, breast cancer, and melanoma with a
great expectation for a cure, a marked antitumor effect
(graft-versus-tumor effect) often accompanies severe
GVHD [15,16]. Thus, NST for solid tumors is now being
performed only in a limited number of institutions.  
Based on the frequent coexistence of a GVL effect with
GVHD in NST and conventional myeloablative stem cell
transplantation (CST), efficient separation of the GVL
effect from GVHD is eagerly anticipated. The separation of
the phenomena appears to be realized by progress in
transplantation immunology, utilization of minor
histocompatibility antigen expression differences between
donor and host, tumor-associated antigens for vaccination
or cytotoxic T-cell induction, cellular therapies, and new
pharmacologic agents. These strategies are beneficial not
only for NST but also for CST to enhance the GVL effect
without inducing severe GVHD.
Nonmyeloablative stem cell transplantation
NST was developed by several investigators with various
conditioning regimens that are different from conventional
myeloablative HSCT (Table 1). The representative CST is
as follows: cyclophosphamide (CY) 60 mg/kg×2 days+
total body irradiation (TBI) 2 Gy×12, busulfan (BU) 1 mg/
kg×16+CY 50 mg/kg×4 days, and VP-16 10 mg/kg×2
days+CY 60 mg/kg×2 days+TBI 2 Gy×6. In contrast, NST
regimens have reduced-intensity compared to those of
CST. Each regimen shows somewhat different GVHD
incidences and GVL effects. The M.D. Anderson Cancer
Center and the UK groups [16-18] use fludarabine (Flu)
30 mg/m
2/day×4-5 days+melphalan (Mel) 140 mg/m
2/
day×1 day±alemtuzumab 20 mg/day×4-5 days. The
Hadassah University Hospital group and others [2,19,20]
use Flu 30 mg/m
2/day×6 days or cladribine 12 mg/m
2/
day×5 days+BU 4 mg/m
2/day×2 days±anti-T-lymphocyte
globulin (ATG) 10 mg/kg/day×4 days. The Massachusetts
General Hospital group uses Flu 30 mg/m
2/day+CY 50
mg/kg/day×4 days+ATG 15 or 30 mg/kg/day×2 days+7
Gy thymic irradiation. The NIH and M.D. Anderson
Cancer Center groups [5,15,21,22] use Flu/CY.  
The Fred Hutchinson Cancer Research Center group
[3,23,24] uses 2 Gy TBI±Flu 30 mg/m
2/day×3 days.
Among reduced-intensity conditioning regimens, Flu/Mel
±alemtuzumab and Flu/BU±ATG are relatively close to
the myeloablative conditioning regimens. In contrast,
Flu/CY and TBI 2 Gy±Flu are milder conditioning regimens
than Flu/BU±ATG and Flu/Mel. Therefore, DLI is often
needed to obtain complete donor chimerism in cases with
the most reduced-intensity conditioning regimens such as
Flu/CY and TBI 2 Gy±Flu. The conditioning regimen
intensity correlates with antileukemic activity, regimen-
related toxicity, and time to achieve complete donor
chimerism. Further descriptions about the differences in
each procedure can be found elsewhere. Delineating the
incidence of GVHD and GVL effects is more important in
NST as well as in CST and it enhances the GVL effect
without augmenting GVHD.
NST induces mixed chimerism, followed by a decreased
early onset of grades II to IV (mild to severe) acute GVHD.
However, late-onset (>100 days after NST) acute GVHD
and chronic GVHD occur similarly to those in CST. Initially,
the incidence and severity of acute GVHD was thought to
be less in NST than in CST because NST results in milder
tissue toxicity and does not induce a cytokine storm, which
is one of the major inducers of acute GVHD and possibly
chronic GVHD [25-28]. Although the incidence and
severity of acute GVHD is somewhat delayed in NST
compared to CST, it is not much different from those of
CST. The only difference is the delayed occurrence of
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Table 1. Intenisty of conditioning regimens
Reduced-intensity
Less intense 2 Gy TBI
(Nionmyeloablative) 2 Gy TBI/Flu
Flu/CY
More intense Flu/BU
Flu/BU/ATG
Flu/Mel
Flu/Mel/Alemtuzumab
Myelablative intensity CY/TBI 
BU/CY
VP/CY/TBI  
TBI, total body irradiation; Flu, fludarabine; CY, cyclophosphamide;
BU, busulfan; ATG, days±anti-T-lymphocyte globulin; Mel, melphalan.Masahiro Imamura and Junji Tanaka. GVL effect in NST    289
acute GVHD in NST as compared to CST and it partly
depends on the delayed establishment of complete donor
chimerism and utilization of DLI to inhibit rejection,
promote engraftment, and enhance the GVL effect. The
DLI dose is not always correlated with GVHD and the
GVL effect and unfortunately both phenomena often
coexist. 
One of the advantages of NST is less toxicity against
various organs and tissues; thus, it is applicable to
older patients and those with limited organ dysfunction.
This is a great advantage for NST because now many
patients can receive allogeneic HSCT in a NST fashion.
Another advantage is the expected recovery of autologous
hematopoiesis, even if engraftment failure occurs;
however, this characteristic is correlated with frequent
mixed chimerism and relapse of leukemias or other
hematological malignancies.
Several studies have shown that the outcomes of older
patients who undergo NST during remission are comparable
to those of patients who receive CST [29-31], suggesting
that the GVL effect associated with NST might be adequate
for controlling chemosensitive or slowly progressing
disease. Although whether NST is feasible for patients
not in remission is controversial [32-35], Maruyama et al.
[36] showed that the GVL effect associated with NST is
comparable to that associated with CST.
Clinical outcome in hematological malignancies
after NST
Clinical outcome in various hematological malignancies
after NST varies from disease to disease and depends on
disease status and its growing capacity (Table 2).
Acute myelogenous leukemia (AML)/
myelodysplastic syndrome (MDS)
Regardless of the various conditioning regimens, the
occurrence of acute GVHD (≥grade II), chronic GVHD,
2-year overall survival (OS), and NST relapse rate are
about 35%, 40%, 40%, and 50%, respectively, suggesting
similar outcomes to those in CST [37,38]. However, NST
is superior to chemotherapy in patients older than 50
years with AML and in those in their first complete
remission [39]. An additional randomized trial is needed
to determine whether NST in younger patients with
AML/MDS is also superior to CST. 
Chronic myelogenous leukemia (CML)
The Israeli group showed that the 5-year disease-free
survival rate for chronic phase CML (CML-CP) is about
85% [40], whereas the European Group for Blood and
Marrow Transplantation showed a 5-year OS of about
60% in CML-CP and about a 20% 5-year OS in accelerated
phase or blastic crisis CML (CML-AP/BC) [41]. Since new
drugs such as imatinib, nilotinib, and dasatinib have been
developed and are extensively effective CML-CP agents,
the frequency of allogeneic HSCT including NST is
decreasing, and allogeneic HSCT is performed only in
cases of advanced-phase CML. More intense conditioning
regimens rather than minimally reduced conditioning
regimens are recommended when NST is chosen for CML
[42]. 
Acute lymphoblastic leukemia (ALL)
Generally, the GVL effect after allogeneic HSCT is
hardly generated in ALL, but some GVL effect may occur
[43-45]. Furthermore, the GVL effect for ALL might be
supported by the result of a retrospective analysis in
Japan, which showed that allogeneic HSCT for ALL was
superior to autologous HSCT and dissimilar to AML [46].
Another aspect of allogeneic HSCT for ALL is to intensify
the conditioning regimen, although NST has more often
been performed for various hematological diseases. In
fact, an excellent outcome (about a 90% 3-year OS) was
observed in allogeneic HSCT using a conditioning
regimen with medium-dose VP-16, cyclophosphamide,
Table 2. Anti-hematological malignancy effects by
NST and DLI
Disease Graft-versus-malignancy effects    
by NST by DLI             
AML/MDS +? ± to +
CML      
CP ± ++ to +++
AP/BC -  - to ±
ALL -? - to ±
CLL +? +
NHL   
High grade - to ± ±   
Low grade + to ++ +  
Multiple myeloma + + 
NST, nonmyeloablative stem cell transplantation; DLI, donor
lymphocyte infusion; AML, acute myelogenous leukemia; MDS,
myelodysplastic syndrome; CML, chronic myelogenous leukemia;
CP, chronic phase; AP, accelerated phase; BC, blast crisis; ALL,
acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia;
NHL, non-Hodgkin’s lymphoma.and total body irradiation for patients with ALL in their
first complete remission [47]. NST is not often performed
for such patients to justify its efficacy for the GVL effect. In
general, because a slight GVL effect may be induced even
by the CST setting, NST is likely inadequate for ALL.
Chronic lymphocytic leukemia (CLL)
CLL is an incurable disease with standard chemotherapy.
Although autologous HSCT shows little evidence of a
beneficial outcome, allogeneic HSCT with myeloablative
conditioning regimens have established high and complete
response rates but often with high TRM [48]. The presence
of a GVL effect in CLL is evident in the induction of complete
remission by DLI [48,49]. Therefore, NST has been applied
to CLL as well. TRM is reduced by NST, but this benefit is
offset by increased relapse rates [50].
Non-Hodgkin’s lymphoma (NHL)
Autologous HSCT is usually performed in patients
with NHL, and allogeneic HSCT is applied to relapsed,
chemoresistant, or poor-prognosis patients. The outcome
of NST for high-grade NHL varies widely [22,51,52]. In
contrast, low-grade, advanced-phase NHLs, especially
follicular lymphoma, are well treated with NST, resulting
in about an 80% 3-year OS [53].
Multiple myeloma
Allogenic HSCT with myeloablative conditioning
regimens is too toxic to patients with multiple myeloma
and results in a higher TRM [54], although a graft-versus-
myeloma effect does exist [55,56]. Single or double
autologous HSCT is often used for multiple myeloma
treatment, but controversial results have been reported
[57,58]. NST following autologous HSCT has also been
examined and results in an excellent outcome [59,60].
However, controversy still exists concerning the outcome
between double autologous HSCT and autologous HSCT
followed by NST [61]. Furthermore, better response rates
are obtained using various new drugs such as tahidomide,
lenalidomide, and bortezomib in combination with
dexamethasone, prednisolone, and/or melphalan, and
when using those as maintenance therapeutic drugs after
single autologous HSCT [62-64]. So, the efficacy of NST
for multiple myeloma has not yet been confirmed.
DLI and graft-versus-hematological malignancy
effects
DLI is often required to achieve complete donor
chimerism in minimally reduced-intensity conditioning
regimens. However, it is not so frequently required to
achieve complete donor chimerism after moderately
reduced-intensity conditioning regimens, which are
similar to myeloablative conditioning regimens; therefore,
it is currently used only for relapse or after an increase in
host cells during a period of mixed chimerism. Table 2
summarizes the anti-hematological malignancy effects
by DLI in various hematological diseases.
Initially, DLI was reported to be markedly effective
against CML relapse after allogeneic HSCT. About 80%
of patients treated with DLI for relapsed CML-CP will
achieve a complete cytogenetic and molecular response
[14,65]. In contrast, only 12-28% of patients with
accelerated phase or blast crisis relapse respond to DLI.
Advanced-phase relapse rates after DLI are high [66,67].
Although DLI results in an excellent GVL effect against
relapsed CML, its effect is disappointing inrelapsed AML,
exhibiting about 20-30% complete remission [14,65].
Furthermore, DLI is less effective for managing post-
transplant MDS. The GVL effect of DLI is not remarkable
in cases of ALL, showing only about a 10% complete
remission [65]. The response rate for DLI in patients with
multiple myeloma is about 30%, but a sustained remission
occurs in 0-18% of patients [55,68-70]. In addition to the
limited response rate, DLI toxicity is significant for
myeloma, with more than half of patients experiencing
acute and chronic GVHD. Therefore, a graft-versus-
myeloma effect has been implicated in other settings
such as RIST or the prophylactic use of DLI following
T-cell-depleted HSCT. [71,72]. Furthermore, new drugs
such as bortezomib and thalidomide are often used for
myeloma in combination with other drugs, so the advantage
of allogeneic HSCT for the treatment of multiple myeloma
is being reconsidered. Although Hodgkin’s lymphoma
(HL) and NHL are susceptible to the DLI graft-versus-
lymphoma effect to some extent [52,73-75], the GVL effect
appears to be readily generated in the NST setting for HL
and low-grade NHL [53,76]. Acute GVHD develops in 19-
33% of DLI after NST, and chronic GVHD occurs in 33-
34%. No statistically significant relationship exists
between GVHD and DLI dose in some occasion [77,78]. 
Chimerism and DLI
DLI is performed to avoid graft rejection or malignancy
relapse and is marginally effective for controlling such
episodes, although not always. A chimerism analysis,
which shows the proportion of donor-derived and host-
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derived cells, is important to determine the appropriate
timing for DLI. Several methods can be used to analyze
chimerism. Among them, using microsatellite DNA as the
RT-PCR probe is useful in terms of accuracy and quantity
[79]. Although donor T-cell chimerism is believed to be a
good indicator for estimating engraftment and rejection,
donor NK-cell chimerism at the early phase after trans-
plantation is also a valuable indicator [79,80]. Because NK
cells recover faster than T cells, donor NK-cell chimerism
predicts subsequent donor T-cell chimerism and engraft-
ment. Murine models suggest the importance of host NK
cells for rejection of allogeneic hematopoietic stem cells
[81-83]. In fact, more frequent rejection occurs when
donor CD56+ NK-cell chimerism is less than 50% on day
14, resulting in an unfavorable outcome [79]. Grade II to
IV acute GVHD develops in patients with more than
50% donor-type chimerism in CD3+ T cells on day 14.
Furthermore, more than 50% of donor-type chimerism in
CD56+ NK cells on day 14 and more than 75% donor-type
chimerism in CD3+ T cells, CD56+ NK cells, and CD14/
15+ myeloid cells on day 28 are associated with a lower
relapse rate. Better 1-year overall survival is shown in
patients with more than 50% donor-type chimerism in
CD56+ NK cells on day 14 and more than 90% donor-type
chimerism in CD14/15+ myeloid cells and CD56+ NK cells
on day 28. 
Regarding the GVL effect, Baron et al. [84] reported that
extensive chronic GVHD, but not acute GVHD, is associated
with a decreased risk of relapse or progression and an
increased probability of progression-free survival. Although
achievement of complete donor chimerism was associated
with a decreased risk for relapse or progression, grade II
to IV acute GVHD had no significant impact on the risk of
relapse or progression but was associated with an increased
risk for non-relapse mortality and decreased probability of
progression-free survival. The reason why acute GVHD
was not associated with an increased probability of
achieving complete remission in their study appeared to
be that corticosteroids and other immunosuppressive
agents used to treat acute GVHD lowered the GVL effect.
In any case, a chimersim analysis on various cell lineages,
such as CD3+ T cells, CD56+ NK cells, and CD14/15+
myeloid cells, is important to estimate the appropriate
timing of DLI and to evaluate the occurrence of rejection,
relapse, and GVHD in NST. 
Role of antigen peesenting cells (APC) in the
induction of GVHD and graft-versus-hematological
malignancy effects
The presence of host-derived APCs during the first
month after NST may be responsible for efficient donor T-
cell immunization against host hematopoietic cells. Strong
antileukemic responses are seen in some patients without
clinical GVHD, suggesting that those responses were
directed against antigens preferentially expressed on
hematopoietic cells, although this situation cannot exclude
the existence of a subclinical level of graft-versus-host
reaction (GVHR). In general, achievement of complete
donor T-cell chimerism is associated with a reduced risk of
relapse or progression, indicating that alloreactivity
against both normal host hematopoiesis (GVHR or
GVHD) and leukemic cells (GVL effect) were effectively
induced. 
However, complete donor chimerism increases non-
relapse mortality. This observation can cause the apparent
strong association between high levels of donor T-cell
chimerism early after NST and the increased risk of more
severe GVHD. Therefore, a transient mixed chimerism
after NST appears to be requisite to induce the GVL effect,
and possibly GVHR/GVHD as well, through donor T-cell
immunization by host APCs. In fact, the absence of host
APCs by day 100 after NST leads to reduced acute GVHD
[85], whereas the GVL effect can be induced by cross-
presentation in which donor T cells are primed with host
leukemia antigens presented by donor APCs [86]. Host
APCs, however, have recently been suggested as being
necessary to induce both the GVHD and GVL effect;
moreover, APCs were also found to be necessary to induce
both the GVHD and GVL effect, showing the absence of a
clear association between donor/host APCs and the
GVHD/GVL effect. Although Matte et al. [87] reported
that GVHD is intensified by donor APCs cross-priming
alloreactive CD8+ T cells, and that donor APCs are not
required for the CD8-mediated GVL effect, Reddy et al.
[88] showed that APCs and alloantigen tumor expression
are crucial for the GVL effect, and that host APCs
predominate in the GVL effect with the contribution of
donor APCs to decrease tumor burden. Furthermore,
donor or host APCs are associated with CD4-mediated
chronic skin GVHD via CD80/CD86 dependent
costimulation, and both donor and host APCs elicit
maximal chronic GVHD, whereas donor APCs play a
dominant role in CD4-mediated intestinal chronic GVHD
via CD40 and CD80/CD86-dependent costimulation[89]. Because host APCs are required to initiate CD8-
mediated acute GVHD [90,91], differences in APC
requirements exist between CD8-mediated acute GVHD
and CD4-mediated chronic GVHD, with target tissue-
specific differences as well. 
Separation of graft-versus-hematological
malignancy effects from GVHD
The separation of the GVL effect from GVHD is one of
the major issues in allogeneic HSCT. Various trials have
been conducted to examine such conditions in murine
models. For example, utilization of a cytokine balance
toward Th1/Tc1 may preferentially lead to the GVL effect.
A special T-cell subset expressing CD62L- CD4+ effector
memory T cells appears to play an important role for
exerting the GVL effect without augmenting GVHD.
Utilization of alloreactive NK cells can deplete host APCs,
resulting in reduced GVHD with a preserving GVL effect.
Blockade of costimulatory molecules such as CTLA4-Ig,
anti-OX40L antibody, and anti-ICOS antibody may
inhibit GVHD and preserve the GVL effect [92-98].
Chemokine and chemokine receptor modulation by the
relevant antibody or antagonist may also inhibit GVHD,
but not the GVL effect [99-108]. Novel pharmacologic
agents such as the proteasome inhibitor bortezomib plus
allogeneic T-cell infusion induce the GVL effect without
enhancing GVHD [109]. Furthermore, the histone
deacetylase inhibitor suberoylanilide hydroxamic acid
induces the GVL effect, but not GVHD [110].
In humans, alloreactive NK cells can inhibit GVHD
and preserve the GVL effect, so in vivo expansion after
allogeneic HSCT and transfer of in vitro-generated
alloreactive NK cells appear to inhibit GVHD, but not GVL
or the graft-versus-tumor effect [91,111-113]. Rapamaycin
appears to induce the GVL effect, inhibiting GVHD in
humans [114,115]. Recently, CCL8 has been shown to be a
molecular candidate for the diagnosis of acute GVHD in
both mice and humans [116,117], and a four protein
fingerprint of interleukin-2 receptor-α, tumor necrosis
factor receptor-1, interleukin-8, and hepatocyte growth
factor in plasma have been identified as biomarkers for
predicting severe acute GVHD [118]. Therefore, determining
whether blocking of these molecules inhibits GVHD and
preserves the GVL effect would be of interest. 
Differences in minor histocompatibility antigen
expression between donor and host can be utilized to
separate the GVL effect from GVHD, although a limitation
exists in exploiting such disparities in terms of difficulty in
HLA-matched donor selection and HLA-restricted
immune response of anti-minor histocompatibility
antigens [119-121]. HA-2 is preferentially expressed on
hematopoietic tissue rather than nonhematopoietic tissue;
therefore, anti-host HA-2-specific T cells induce the GVL
effect without augmenting GVHD. In contrast, HA-1 is
expressed on both hematopoietic and non-hematopoietic
tissues, and HA-3 is preferentially expressed on non-
hematopoietic tissues, suggesting that these minor
histocompatibility antigens are not suitable to induce only
the GVL effect.  The Y chromosome encodes male-specific
minor histocompatibility (HY) antigens such as UTY,
SMCY, and DBY; therefore, anti-HY-specific T cells can be
induced after female to male allogeneic HSCT [122-124].
Because only UTY is modestly expressed on host epithelial
cells, anti-UTY-specific T cells may lead to the GVL effect
without augmenting GVHD. In contrast, SMCY and DBY
are highly expressed on epithelial cells, thus causing anti-
SMCY- and DBY-specific T cells that appear to induce
both GVHD and the GVL effect. Furthermore, DDX3Y,
which is expressed on leukemic stem cells, appears to be
a suitable target for the GVL effect, but not for GVHD,
because DDX3Y expression is detected in all myeloid and
lymphoid leukemic cells that carry an intact Y chromosome
[125].  
Other candidate antigens that exert only the GVL effect,
but not GVHD, are as follows: proteinase 3, which is
aberrantly expressed or overexpressed in AML and CML
[126-128]; WT-1 in AML, CML, and multiple myeloma
[129-132]; survivin for AML, CML, CLL, and lymphoma
[133-136]; idiotype for multiple myeloma [137]; and BCR-
ABL [138] for CML. In vitro-generated cytotoxic T cells
against various minor histocompatibility antigens can be
used for adoptive transfer, and peptide vaccine trials for
BCR-ABL, PR1 derived from PR3, and WT1 are being
examined. The efficacy of the BCR-ABL vaccine is limited
in patients with low levels of residual and stable disease.
In contrast, the PR1 and WT1 vaccines are more beneficial,
resulting in better clinical responses [139]. However,
vaccination therapy with only these peptides is not enough
to obtain a sufficient clinical outcome. Recently, unique
HLA-mismatch combinations between donor and host
HLA-C expression have been correlated with the induction
of an efficient GVL effect without augmenting GVHD by a
retrospective analysis using data from the Japan Marrow
Donor Program [140,141]. This type of approach is one of
the candidates for separating the GVL effect from GVHD,
although great genetic differences exist among nations
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regarding GVHD and HLA disparities. 
CONCLUSION
The efficacy and limitations of NST are becoming
clearer because this procedure alone cannot sufficiently
induce the graft-versus-hematological malignancy effect
except for certain diseases, even in combination with DLI.
Therefore, future progress in transplantation immunology
is needed, so that we are able to efficiently separate
graft-versus-hematological malignancy from GVHD.
Furthermore, NST should be combined with various
strategies such as the utilization of minor histocompatibility
antigen expression differences, vaccination, or induction
of cytotoxic T cells using tumor-associated antigens and
other cellular therapies to enhance the graft-versus-
hematological malignancy effect without augmenting
GVHD.
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